Research company Research Centers of America (RCA) said on Tuesday that it is recruiting volunteers to participate in the clinical investigations of COVID-19 vaccines by several big companies under Operation Warp Speed, the Federal Government protocol and US FDA.
The RCA's medical director Dr Howard Schwartz participated in a conference with vice president Mike Pence, school leaders and members of the Miller School of Medicine, along with several other researchers working together to end the battle against COVID-19.
RCA will recruit between 300 and 500 participants solely for the Moderna study, under which, approximately 30,000 participants are expected to enroll in the US. The randomized, placebo-controlled study is expected to investigate a mRNA-1273 dose of 100 µg. The primary objective will be prevention of symptomatic COVID-19 disease.
To ensure the safety and ongoing monitoring of study participants, the data will be reviewed by an independent Data and Safety Monitoring Board organized by NIAID throughout the study, concluded RCA.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma